In line with this, a recent study found that genetic ablation of microglial HDAC1 and HDAC2 in an AD mouse model reduced amyloid plaque burden and rescued memory deficits,54 suggesting HDAC modulation in microglia as a potential therapeutic target. The gene discussed is HDAC2; the disease is amyloidosis.